コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 garding all-cause mortality in patients with heart failure with reduced ejection fraction.
2 increasing aerobic capacity in patients with heart failure with reduced ejection fraction.
3 ects reduce those processes that can lead to heart failure with reduced ejection fraction.
4 ucture and function have not been studied in heart failure with reduced ejection fraction.
5 -right interatrial shunting in patients with heart failure with reduced ejection fraction.
6 ared with enalapril therapy in patients with heart failure with reduced ejection fraction.
7 Impaired contractility is a feature of heart failure with reduced ejection fraction.
8 l and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.
9 prevalent therapy for patients with Stage D heart failure with reduced ejection fraction.
10 ith heart failure, HFpEF is now as common as heart failure with reduced ejection fraction.
11 being developed as a potential treatment for heart failure with reduced ejection fraction.
12 the first study to evaluate elamipretide in heart failure with reduced ejection fraction and demonst
14 aptive servo-ventilation in patients who had heart failure with reduced ejection fraction and predomi
15 on the primary end point in patients who had heart failure with reduced ejection fraction and predomi
16 e analyzed data from 40,195 patients who had heart failure with reduced ejection fraction and were en
17 ter prevalence of coronary artery disease in heart failure with reduced ejection fraction and with a
19 ists (MRA) reduce morbidity and mortality in heart failure with reduced ejection fraction but can cau
20 ing disease severity in patients with stable heart failure with reduced ejection fraction, but less i
22 cal advertisement and included patients with heart failure with reduced ejection fraction diagnosed b
23 trolled, ascending-dose trial, patients with heart failure with reduced ejection fraction (ejection f
24 ection fraction (HFbEF) (EF 41% to 49%), and heart failure with reduced ejection fraction (HFrEF) (EF
25 ty of cardiac rehabilitation (CR) to include heart failure with reduced ejection fraction (HFrEF) as
28 h preserved ejection fraction (HFPEF) versus heart failure with reduced ejection fraction (HFREF) hav
29 rved ejection fraction (HFpEF) compared with heart failure with reduced ejection fraction (HFrEF) in
30 uideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) is
31 ves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), co
32 x control plays a role in the progression of heart failure with reduced ejection fraction (HFrEF), th
33 with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
34 with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
35 with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
36 as common and may have similar mortality as heart failure with reduced ejection fraction (HFREF).
37 ntagonist (AldA) therapies for patients with heart failure with reduced ejection fraction (HFrEF).
38 on (HFPEF) may be as common and as lethal as heart failure with reduced ejection fraction (HFREF).
39 fibrillator (ICD) therapies in patients with heart failure with reduced ejection fraction (HFrEF); ye
40 s are indicated in patients with symptomatic heart failure with reduced ejection fraction; however, t
41 giotensin receptor blockers in patients with heart failure with reduced ejection fraction improve out
42 heart rate remains unclear for patients with heart failure with reduced ejection fraction in either s
43 ic importance of heart rate in patients with heart failure with reduced ejection fraction in randomiz
44 a-blockers reduce mortality in patients with heart failure with reduced ejection fraction in sinus rh
45 Myocardial remodeling in HFPEF differs from heart failure with reduced ejection fraction, in which r
46 uce mortality and morbidity in patients with heart failure with reduced ejection fraction, including
47 mposition during progressive decongestion in heart failure with reduced ejection fraction is characte
48 oratory monitoring before MRA initiation for heart failure with reduced ejection fraction is common,
49 comes in patients hospitalized for worsening heart failure with reduced ejection fraction is unclear.
50 new drugs, both for the treatment of chronic heart failure with reduced ejection fraction: ivabradine
51 ydralazine-isosorbide dinitrate (H-ISDN) for heart failure with reduced ejection fraction reduced mor
52 efficacy of many therapies for patients with heart failure with reduced ejection fraction, such as an
53 al of therapy for hospitalized patients with heart failure with reduced ejection fraction, this measu
54 k Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enroll
55 We now have many successful treatments for heart failure with reduced ejection fraction, while spec
56 lly over time among ambulatory patients with heart failure with reduced ejection fraction who were en
57 nitoring among 490 patients hospitalized for heart failure with reduced ejection fraction who were su
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。